NADH and Jet Lag: What a NASA-Era Study Found About Cellular Recovery

The NASA-era NADH jet lag study, in brief

In 2001, a research team led by neuropsychologist Gary Kay, working with the Washington Neuropsychological Institute and NASA Johnson Space Center, published results from a clinical trial examining whether stabilized sublingual NADH could reduce the cognitive effects of jet lag.

The study enrolled thirty-five healthy, employed adults who trained and underwent baseline testing on the West Coast before flying overnight to the East Coast — a three-hour time shift. On arrival, participants were randomly assigned to receive either 20 mg of sublingual stabilized NADH or identical placebo tablets.

The following morning and afternoon, they completed computer-administered cognitive tests, including the CogScreen battery used in aviation medicine, as well as measures of mood and sleepiness.

What the NADH jet lag trial measured

The research team tracked three outcomes: cognitive performance, subjective sleepiness, and mood. Jet lag produced sleepiness in more than half the participants and measurable deterioration of cognitive functioning in roughly a third.

The morning after the flight, subjects showed lapses in attention, disruptions in working memory, reduced divided attention, and slower visual-perceptual speed.

These are the classic cognitive signatures of jet lag — the reasons a red-eye flight leaves travelers unable to hold a thought, answer an email, or navigate a new airport without effort.

What the NADH group experienced

Participants who received the 20 mg sublingual NADH dose performed significantly better on five of eight cognitive and psychomotor test measures, with a trend toward better performance on the remaining three. They also reported less sleepiness than the placebo group. No adverse effects were observed with NADH treatment.

The authors' conclusion was unambiguous: stabilized NADH significantly reduced jet lag-induced disruptions in cognitive functioning, was easily administered, and had no adverse side effects.

A single sublingual dose of NADH produced measurable improvements in cognitive performance after time-zone travel. The effect appeared on objective cognitive tests, not just subjective ratings. The study design was double-blind and placebo-controlled. The results were published under NASA Johnson Space Center authorship.

Why jet lag is a cellular energy problem, not a sleep problem

Jet lag is commonly described as a sleep disorder. Biologically, it is closer to a cellular energy crisis with sleep symptoms layered on top.

When a traveler crosses time zones, the body's internal clock — the circadian rhythm that governs hormone release, body temperature, appetite, cognition, and alertness — falls out of alignment with the local environment.

The brain begins producing cortisol to wake up at what local time insists is dinner. The liver is metabolizing food as if it is 4 a.m. when the menu is being presented for a late lunch. Cellular processes across the body are asked to perform on a schedule they are not prepared for.

The consequences are metabolic.

Every cell in the body depends on a steady supply of ATP — the energy currency produced primarily in the mitochondria. That ATP production depends on a continuous cycle between NAD+ and NADH, the oxidized and reduced forms of the same coenzyme. When the circadian clock destabilizes, the NAD+/NADH cycle does as well.

This is why jet lag feels the way it does. The foggy thinking, the flat mood, the afternoon collapse, the inability to summon ordinary mental energy — these are not simply the result of lost sleep. They result from cellular energy production falling out of rhythm.

How NADH works in the body

NADH is the reduced, electron-carrying form of nicotinamide adenine dinucleotide (NAD+). In every cell, NAD+ is continuously converted to NADH as it picks up electrons from the breakdown of food.

NADH then delivers those electrons to the mitochondrial electron transport chain, where they drive the production of ATP — the molecule your body spends to think, move, and stay awake.

The ratio of NAD+ to NADH sets the pace of cellular energy production. A healthy ratio supports efficient ATP synthesis. A disrupted ratio slows it down.

As the NASA-era study authors noted, NADH increases cellular ATP production and facilitates dopamine synthesis — two mechanisms that directly counteract the cognitive slowdown and flat mood characteristic of jet lag. Dopamine is the neurotransmitter most closely associated with alertness, motivation, and focused attention.

Supporting its synthesis at a moment when the brain is struggling to produce it is a plausible mechanism for the cognitive improvements observed in the study.

A sublingual NADH lozenge, delivered at the right moment, provides cells with an additional electron-carrying substrate precisely where the body most needs it.

Crossing time zones disrupts circadian rhythm, which disrupts the NAD+/NADH cycle that produces cellular energy. Supporting that cycle directly is what the NASA-era study was designed to test — and what the results support.

NAD+ and NADH: the difference that matters

NAD+ and NADH are two forms of the same molecule. NAD+ is the oxidized form — ready to accept electrons. NADH is the reduced form, carrying the electrons it has picked up. The cycle between them is continuous and forms the foundation of virtually every energy-producing pathway in the body.

The NASA-era study used NADH directly. The broader NAD+ supplement category — including precursors like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — generally targets the same cellular system from a different angle by raising NAD+ levels, enabling the body to produce more NADH on demand.

Both strategies target the same underlying infrastructure: the cellular energy machinery that determines how efficiently your body produces ATP and how well it holds up under metabolic stress, such as time-zone travel.

Why does jet lag hit harder with age?

NAD+ levels decline with age. Multiple peer-reviewed reviews, including in Nature Reviews Molecular Cell Biology and Cell Metabolism, have documented meaningful reductions in tissue NAD+ availability with aging, particularly in skeletal muscle and parts of the brain.

The decline is accelerated by the ordinary stresses of adult life — poor sleep, chronic stress, alcohol consumption, inflammation, and environmental exposure.

This has direct implications for jet lag.

A forty-five-year-old executive flying from New York to Tokyo is not processing the disruption of time-zone travel through the same cellular environment as a twenty-four-year-old doing the same route. The symptoms may look similar on the surface. The biology underneath is not.

The older traveler is asking a cellular energy system with reduced cofactor availability — and likely further depleted by pre-trip stress and poor sleep — to absorb a metabolic shock it is less equipped to handle.

This is part of why some travelers shake off jet lag in a day while others spend a week crawling back to baseline. It is not simply willpower, hydration, or melatonin timing. It is the cofactor environment the body brings to the flight.

Jet lag recovery slows with age, and the biology is not mysterious. NAD+ availability declines over the decades. The metabolic disruption of travel lands in a body with fewer cellular energy reserves to absorb it. Supporting the underlying cofactor system becomes more consequential with each decade.

What serious travelers are doing about NADH and NAD+

In the years since the NASA-era study, the consumer landscape has evolved in ways that align with the research's predictions.

Sublingual NADH lozenges — the same format used in the original trial — remain available from several supplement brands. NAD+ precursor supplements such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) have become established categories with growing human clinical research behind them.

IV NAD+ therapy has moved from fringe clinics into mainstream wellness offerings in major travel hubs, often marketed specifically to business travelers and long-haul flyers. NAD+ beverages — a newer category of functional drinks designed to support daily cellular energy — have begun appearing on shelves, aimed at consumers who want a steady baseline rather than an acute intervention.

None of these is exclusively a jet lag intervention. But the underlying logic is consistent: when the body's cellular energy system is challenged — by travel, by age, by stress, by modern life — supporting the cofactors at the center of that system is a reasonable strategy with a real mechanism behind it.

Does NADH actually help with jet lag? A straight answer

Based on the available research, yes — with appropriate caveats.

The 2001 NASA-affiliated study remains the most rigorous clinical examination of NADH specifically for jet lag. It was a double-masked, placebo-controlled trial with objective cognitive outcomes and a clear positive result. The mechanism is biologically sound, the safety profile was clean, and the finding aligns with a much larger body of research on NAD+ biology that has emerged in the two decades since.

The caveats: the trial was small (35 participants), examined a relatively modest 3-hour time shift rather than the severe 8- to 12-hour shifts that produce the worst jet lag, and used a specific stabilized sublingual NADH formulation that may not correspond exactly to every product on the market today. Larger replication trials would strengthen the case.

What the study does establish, beyond reasonable dispute, is that cellular energy cofactors appear to play a real role in how the body absorbs time-zone disruption, and that directly supporting those cofactors is a credible strategy with a documented mechanism.

How to use NADH for jet lag

The study protocol used a single 20 mg sublingual dose of stabilized NADH, administered the morning after arrival at the new destination. Sublingual administration — dissolving the tablet under the tongue — allows the compound to bypass digestion and enter the bloodstream more directly.

For travelers interested in applying the approach, a few practical principles follow from the research:

The intervention is cofactor-based, not sedative. NADH supports cellular energy production, which means it is designed to help the body function during the waking hours after arrival, not to help the traveler sleep. It should not be confused with melatonin, which targets the sleep side of the circadian equation.

Timing matters. The original study delivered NADH the morning after the flight, when participants needed to perform cognitively. This timing aligns with the underlying mechanism: supporting energy production when energy is in demand.

NADH and NAD+ strategies can complement, rather than replace, other evidence-based jet lag practices. Light exposure, sleep timing, hydration, and avoiding alcohol on flights all continue to matter. Supporting cellular energy does not replace behavior; it operates on the biology underneath behavior.

They think about cellular infrastructure, not just sleep hygiene. Light timing, hydration, and sleep strategy still matter. But the cellular energy system that has to absorb whatever disruption the flight produces is what determines how well the traveler actually recovers.

The limits of the 2001 research

A few honest limitations deserve naming.

The Kay study involved only thirty-five participants and examined a three-hour time shift. Larger trials, particularly involving the longer and more disruptive shifts typical of transatlantic or transpacific travel, have not replicated the finding with equivalent rigor.

The broader scientific community's understanding of how best to support NAD+ biology has also evolved since 2001, with more recent research focusing on precursor strategies (NR, NMN) rather than on NADH itself.

None of this invalidates the study. It means the finding is a well-designed data point rather than a final verdict. The direction of the evidence, across the NASA-era trial and the much larger body of NAD+ biology research that has followed, consistently points at the same conclusion: cellular energy cofactors matter for how the body handles metabolic stress, including the metabolic stress of travel.

---

Frequently asked questions

What is NADH?

NADH is the reduced form of nicotinamide adenine dinucleotide (NAD+), a coenzyme present in every cell of the body. It carries electrons from the breakdown of food to the mitochondria, where those electrons drive the production of ATP — the molecule cells use for energy.

What dose of NADH did the NASA-era study use?

The study used a single 20 mg sublingual dose of stabilized NADH, administered the morning after arrival at the new time zone.

Is NADH the same as NAD+?

NADH and NAD+ are two forms of the same molecule. NAD+ is the oxidized form; NADH is the reduced (electron-carrying) form. The body continuously cycles between them as part of cellular energy production.

Is NADH safe?

The NASA-era study reported no adverse effects in participants who received NADH. Broader safety research on NADH and NAD+ precursors has been generally favorable, though individual travelers with specific health conditions should consult a medical professional before starting any supplement.

How does NADH compare to melatonin for jet lag?

They work on different mechanisms. Melatonin targets the sleep side of the circadian equation, helping signal the body to rest. NADH supports the cellular energy side, helping the body function during waking hours. The two are not competitors; they address different aspects of the same underlying disruption.

Can NAD+ supplements (NR, NMN) produce similar effects?

The underlying logic is similar — both NADH and NAD+ precursors support the same cellular energy system. However, the 2001 study used NADH specifically, and direct head-to-head comparisons for jet lag have not been published.

---

Sources:

Kay, G. G., Viirre, E., Clark, J. "Stabilized NADH as a Countermeasure for Jet Lag." NASA Johnson Space Center, Report JSC-CN-6528, 2001. Publicly available through the NASA Technical Reports Server: https://ntrs.nasa.gov/citations/20100033641

Covarrubias, A. J., et al. "NAD+ metabolism and its roles in cellular processes during aging." Nature Reviews Molecular Cell Biology, 2020.

Camacho-Pereira, J. et al. "CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism." Cell Metabolism, 2016.